Agonists at cannabinoid receptors, such as the phytocannabinoid Δ(9)-tetrahydrocannabinol, exert a remarkable array of therapeutic effects but are also associated with undesirable psychoactive side effects. Conversely, targeting enzymes that hydrolyze endocannabinoids (eCBs) allows for more precise fine-tuning of cannabinoid receptor signaling, thus providing therapeutic relief with reduced side effects. Here, we report the development and characterization of an inhibitor of eCB hydrolysis, UCM710, which augments both N-arachidonoylethanolamine and 2-arachidonoylglycerol levels in neurons. This compound displays a unique pharmacological profile in that it inhibits fatty acid amide hydrolase and α/β-hydrolase domain 6 but not monoacylglycerol lipase. Thus, UCM710 represents a novel tool to delineate the therapeutic potential of compounds that manipulate a subset of enzymes that control eCB signaling. 
Agonists at cannabinoid receptors, such as the phytocannabinoid ⌬ 9 -tetrahydrocannabinol, exert a remarkable array of therapeutic effects but are also associated with undesirable psychoactive side effects. Conversely, targeting enzymes that hydrolyze endocannabinoids (eCBs) allows for more precise fine-tuning of cannabinoid receptor signaling, thus providing therapeutic relief with reduced side effects. Here, we report the development and characterization of an inhibitor of eCB hydrolysis, UCM710, which augments both N-arachidonoylethanolamine and 2-arachidonoylglycerol levels in neurons. This compound displays a unique pharmacological profile in that it inhibits fatty acid amide hydrolase and ␣/␤-hydrolase domain 6 but not monoacylglycerol lipase. Thus, UCM710 represents a novel tool to delineate the therapeutic potential of compounds that manipulate a subset of enzymes that control eCB signaling.
N-Arachidonoylethanolamine (AEA)
2 and 2-arachidonoylglycerol (2-AG) are lipid transmitters that act as endogenous ligands for the cannabinoid receptors CB 1 and CB 2 . In the central nervous system, these endocannabinoids (eCBs) are produced by neurons and glial cells in response to specific stimuli and are rapidly inactivated by cellular uptake and enzymatic hydrolysis (1) . The eCB signaling system regulates a wide array of physiological processes, including cell differentiation and viability, neurotransmission, and immune cell activation and migration. As such, the enzymes and receptors belonging to the eCB signaling system represent attractive therapeutic targets.
Unlike classical neurotransmitter systems in which signaling diversity is principally accomplished via multiple receptor subtypes for a single endogenous ligand, the eCB signaling system utilizes multiple endogenous ligands, two of which, AEA and 2-AG, have been studied in detail (2) (3) (4) . Enzymes that produce and inactivate these eCBs are tightly and, for the most part, independently regulated (5) . Thus, targeting these enzymes allows for the discrete manipulation of eCB signaling, laying the groundwork for focused therapeutic approaches. However, the respective roles of AEA and 2-AG in modulating neuronal and glial cell functions are still being delineated.
With regard to eCB inactivation, AEA is hydrolyzed mainly by FAAH, and accordingly, selective FAAH inhibition increases AEA levels in neurons without affecting 2-AG levels (6) . In vivo FAAH inhibition recapitulates a narrow subset of the behavioral effects produced by CB 1 agonists (7). 2-AG is hydrolyzed by at least two enzymes: monoacylglycerol lipase (MAGL) (8) and ␣/␤-hydrolase domain 6 (ABHD6) (9) . Selective MAGL inhibition increases 2-AG levels in neurons without affecting AEA levels (8, 10) . In vivo MAGL inhibition recapitulates most of the behavioral effects induced by CB 1 agonists (a phenotype that is largely independent of that of FAAH inhibition), suggesting a functional segregation between AEA and 2-AG signaling pathways in vivo (11) . Concomitant inhibition of FAAH, MAGL, and ABHD6 in vivo increases the levels of both AEA and 2-AG in brain and recapitulates the complete behavioral phenotype induced by direct CB 1 agonists (12) . Selective inhibition of ABHD6 in vivo has so far not been reported. Together, these results suggest that some cell functions are controlled by AEA, some are controlled by 2-AG, and some are controlled by both of these eCBs. With these concepts in mind, we sought to develop novel inhibitors of eCB hydrolysis to expand the available repertoire of pharmacological tools for the exploration and exploitation of eCB signaling. Here, we describe one such compound, UCM710 (compound 12), which is a dual inhibitor of FAAH and ABHD6.
EXPERIMENTAL PROCEDURES
Synthesis of Compounds-IR spectra were determined on a Shimadzu 8300 infrared spectrophotometer. Optical rotation was measured using a PerkinElmer Life Sciences 781 polarimeter. 1 H and 13 C NMR spectra were recorded on a Bruker AVANCE 3000-AM instrument. Chemical shifts (␦) are expressed in parts/million relative to internal tetramethylsilane; coupling constants (J) are in hertz. MS was carried out on a Bruker LC-Esquire spectrometer in electrospray mode. TLC was performed on Merck Silica Gel 60 F 254 plates. For normal pressure chromatography, Merck Silica Gel 60 (size 70 -230) was used. The starting materials used were high-grade commercial products from Aldrich, Acros, or Fluka. Arachidonic, oleic, palmitoleic, ␥-linolenic, and linoleic acids (Ն99% purity) were purchased from Sigma. Spectroscopic data of all described compounds were consistent with the proposed structures. Satisfactory HPLC chromatograms were also obtained for the final compounds (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) , and elemental analyses (carbon, hydrogen, and nitrogen) for these compounds were obtained on a LECO CHNS-932 apparatus (analysis services of the Universidad Complutense de Madrid) and were within 0.5% of the theoretical values, confirming a purity of at least 95% for all tested compounds.
Compounds 1-12 were synthesized according to the method described previously (13) . Briefly, to a stirred solution of 1 eq (100 mg) of carboxylic acid in dry dichloromethane (0.82 ml/mmol) and the appropriate alcohol (5 eq) in dry dichloromethane (0.27 ml/mmol) in an ice bath under argon was added dropwise a solution of dicyclohexylcarbodiimide (1 eq) and catalytic amounts of N,N-dimethyl-4-aminopyridine (0.068 eq) in dry dichloromethane (1.9 ml/mmol). The mixture was stirred for 5 min at this temperature and then removed from the cooling bath and stirred at room temperature (3-6 h) until no further evolution was observed by TLC. The dicyclohexylurea was filtered off, and the filtrate was washed with saturated NaHCO 3 . The organic extracts were dried over anhydrous Na 2 SO 4 . The solvent was then evaporated under reduced pressure, and the product was purified by column chromatography on silica gel using the appropriate eluent.
As a representative example, the complete characterization of compound 12 (UCM710) is given: (Ϯ)-oxiran-2-ylmethyl (9Z)-hexadec-9-enoate (12) Cell Culture-COS-7 cells were expanded in DMEM (HyClone catalog no. SH30243.01) supplemented with HEPES (10 mM), NaHCO 3 (10 mM), penicillin (100 units/ml), streptomycin (100 g/ml), and FBS (10%; HyClone catalog no. SH30071.03). Cells (ϳ90% confluent in 10-cm dishes) were transfected with expression vectors (mouse (m) FAAH, mMAGL, or mABHD6 in pcDNA3 plasmids (3 g/dish), Open BioSystems) using Lipofectamine TM 2000. After 4 -6 h, the medium was changed, and the cells were incubated for an additional 30 -36 h in DMEM ϩ FBS (10%) before use in experiments. The enzymatic activity of mock-transfected COS-7 cell homogenates was 4.0 nmol of 2-AG/mg/min, whereas there was no detectable AEA hydrolysis in these homogenates. The enzymatic activities measured in mMAGL-transfected and mABHD6-transfected COS-7 cell homogenates were 68 and 5.2 nmol of 2-AG/mg/min, respectively. The enzymatic activity in mFAAH-transfected COS-7 cell homogenates was 0.8 nmol of AEA/mg/min. Mouse neurons in primary culture were prepared as described (14) according to the guidelines of the Institutional Animal Care and Use Committee of the University of Washington. Briefly, 1-day-old mouse brains (C57BL/6) were collected, and their meninges and cerebellums were removed. The remaining brain tissue was chopped, and the cells were dissociated and plated in 10-cm dishes (BD Falcon) coated with poly-D-lysine (0.1 mg/ml) at 5.0 ϫ 10 5 cells/ml of Neurobasal Medium (Invitrogen catalog no. 21103-049) supplemented with B-27 (2%), GlutaMAX (1%), penicillin (100 units/ml), and streptomycin (100 g/ml). Neurons were tested after 7-8 days in culture.
2-[ 3 H]AG and [ 3 H]AEA Hydrolysis in Cell
Homogenates and Intact Cells-Cell homogenates were prepared as described previously (15) and added to silanized glass tubes containing 100 l of Tris-HCl buffer (100 mM, pH 7.4) supplemented with fatty acid-free BSA (0.1%), 2-[ 3 H]AG (ϳ1 nM, 40 Ci/mmol; obtained from American Radiolabeled Chemicals) or [ 3 H]AEA (ϳ1 nM, 60 Ci/mmol; obtained from American Radiolabeled Chemicals), and inhibitors or vehicle (dimethyl sulfoxide, 0.1%). Tubes containing this solution but without cell homogenate were used as controls for non-enzymatic hydrolysis ("blank"), and this value was systematically subtracted from values obtained with homogenates. Tubes were incubated for 10 min in a shaking water bath at 37°C. Reactions were stopped by the addition of ice-cold CH 3 OH/CHCl 3 (1:1, 2 ml) and vortexing. The hydrophobic and hydrophilic phases were separated by centrifugation (800 ϫ g, 10 min). One ml of the upper phase was recovered and mixed with Ecoscint (4 ml) for determination of radioactivity by liquid scintillation. Linear enzymatic activity with a set amount of protein was systematically verified and chosen for each homogenate (supplemental Fig. 1 ), as well as for the intact cell experiments (supplemental Fig. 2) . For intact cells, the following solution was prepared in a silanized glass vial and allowed to equilibrate at room temperature for 75 min: HEPES/bicarbonate buffer containing NaCl (120 mM), KCl (5 mM), CaCl 2 (2 mM), MgSO 4 (1 mM), NaH 2 PO 4 (1 mM), glucose (10 mM), NaHCO 3 (5 mM), and HEPES (20 mM) supplemented with BSA (0.15%) and 2- eCB Levels-Neurons grown in 10-cm dishes (one dish/condition) were pretreated for 30 min with inhibitors (10ϫ) or vehicle (dimethyl sulfoxide, 0.1%) by the addition of 1 ml directly to the medium (37°C, shaking water bath). To stimulate the neurons, 1 ml of glutamate (100 M) and carbachol (1 mM) was added for an additional 2.5 min (in the continued presence of the inhibitor) (16) . The reaction was stopped by collecting the medium and adding 5 ml of ice-cold CH 3 OH. 2-AG and AEA were extracted and purified, and their levels were determined as described (17) . Briefly, the cell medium and homogenate were added to CHCl 3 
RESULTS
To develop novel inhibitors of eCB hydrolysis, we designed and synthesized a series of esters that were based on the 2-AG scaffold but with its glycerol moiety replaced by different oxygenated heterocycles (except compound 7, which contains a Michael acceptor) (13) . These derivatives conserved the arachidonic acid moiety (compounds 1-8) or other relevant fatty acid moieties ranging from one to three unsaturations (compounds 9 -12). These compounds were tested for their ability to inhibit AEA and 2-AG hydrolysis in neuron homogenates, with the goal of identifying compounds with high potency against these two enzymatic activities. We found that all 12 compounds inhibited both AEA and 2-AG hydrolysis in neuron homogenates with IC 50 values between 0.2 and 32 M (Table 1) .
In neurons, AEA hydrolysis is mediated by FAAH, and 2-AG hydrolysis is mediated by MAGL and ABHD6 (10) . To determine the selectivity of these 12 compounds for these enzymes, we tested their ability to inhibit eCB hydrolysis in homogenates prepared from COS-7 cells heterologously expressing FAAH, MAGL, or ABHD6. Table 1 summarizes the IC 50 values for compounds 1-12. Remarkably, three of the compounds that we tested (7, 11, and 12) inhibited FAAH and ABHD6 activities without significantly affecting MAGL activity.
We focused the next set of experiments on compound 12, as it exhibited the highest potency against FAAH and ABHD6, as well as the highest selectivity versus MAGL. Specifically, compound 12 dose-dependently inhibited AEA hydrolysis by FAAH and 2-AG hydrolysis by ABHD6 (IC 50 ϭ 4.0 and 2.4 M, respectively) and had no effect on 2-AG hydrolysis by MAGL (Fig. 1A) . Furthermore, this compound was tested for its ability to interact with CB 1 Compound 12 efficiently inhibited eCB hydrolysis in neuron homogenates, but this does not necessarily mean that it is efficacious in intact cells. To address this question, we measured eCB hydrolysis by intact neurons in primary culture in the presence of compound 12 and found that it inhibited AEA and 2-AG hydrolysis in intact neurons by 60 and 30%, respectively (Fig. 1B) . Thus, compound 12 is a dual inhibitor of FAAH and ABHD6 that retains its efficacy in intact neurons, although not fully inhibiting these activities.
Inhibition of eCB hydrolysis in intact neurons typically increases only the stimulated accumulation of AEA and 2-AG, not the basal level of these eCBs (10) . To assess the effect of compound 12 on eCB accumulation in neurons in primary culture, AEA and 2-AG levels under both basal and stimulated conditions were quantified by chemical ionization GC-MS. The stimulation protocol consisted of treatment with glutamate (100 M) and carbachol (1 mM) for 2.5 min, which increases eCB production in these cells (16) . Compound 12 had no effect on the basal levels of AEA or 2-AG in neurons, but both of these eCBs were significantly increased under stimulated conditions (Fig. 1, C and D) , suggesting that inhibition of ABHD6 and FAAH is sufficient to increase the stimulated accumulation of 2-AG and AEA in intact neurons, even when MAGL activity is preserved.
DISCUSSION
Considering the plethora of medicinal effects produced by drugs activating cannabinoid receptors, there is growing interest in understanding the therapeutic potential of compounds targeting specific enzymes of the eCB signaling system to develop treatments that lack the typical side effects associated with cannabinoid agonists. Enzymes that regulate the levels of eCBs constitute attractive targets because they represent control points within the eCB signaling system. For example, in vivo inhibition of FAAH causes a selective elevation of AEA levels in brain, which results in significant reductions in pain, anxiety, and depression while not inducing other common cannabinoid behavioral effects such as body temperature reduction and catalepsy (7) . On the other hand, in vivo inhibition of MAGL causes a robust elevation of 2-AG levels in brain, but the therapeutic efficacy of targeting this enzyme is limited by the observation that chronic MAGL inhibition results in a significant desensitization of CB 1 receptors in the brain (5). Because MAGL is the dominant 2-AG hydrolase in adult brain (9) , it is perhaps not surprising that inhibition of this enzyme has a profound stimulatory effect on the eCB signaling system in vivo, resulting in an "overflow" of 2-AG that causes compensatory adaptations similar to what is seen with chronic administration of direct CB 1 receptor agonists (19) . In support of this view, it is worth noting that 2-AG is a potent full agonist at cannabinoid receptors, whereas AEA is a partial agonist, and 2-AG is much more abundant in brain than AEA (20, 21) . Thus, it is important to assess the therapeutic potential of targeting other 2-AG hydrolases, such as ABHD6, to determine whether a moderate reduction of 2-AG hydrolysis represents the key to operating within the "therapeutic window" of enhanced 2-AG signaling. Indeed, because ABHD6 has a different expression pattern than MAGL (10, 22) and also exhibits less intrinsic enzymatic activity than MAGL (9), ABHD6 inhibition is likely to lead to a differential activation profile of CB 1 receptors in brain compared with MAGL inhibition. Furthermore, considering that some of the functions of the eCB signaling system are mediated by AEA and 2-AG working together, concomitant inhibition of FAAH and ABHD6 has the potential to provide unique therapeutic benefits.
We have reported the development of a series of structurally similar "substrate-mimicking" inhibitors of eCB hydrolysis.
The most potent inhibitor of the series, compound 12, and two additional compounds, 7 and 11, display a unique pharmacological profile in that they inhibit FAAH and ABHD6 but not MAGL. This raises the question of how these compounds manage to attain such selectivity. Having been developed as substrate-mimicking inhibitors, these compounds presumably exert their effects by interacting directly with the active sites of these enzymes rather than by modulating their enzymatic activity via an allosteric site (23) . Thus, our results suggest that competitive inhibitors that contain a 2-(acryloyloxy)ethyl headgroup (compound 7) or an oxiran-2-yl headgroup (compounds 11 and 12) will not fit into the active site of MAGL. When considering the differences between the active site of MAGL and the active sites of FAAH and ABHD6, a striking feature is the unique cap domain that covers the MAGL active site, confirmed by the analysis of the crystal structure of human MAGL (24) . This cap domain is involved in substrate recognition and is crucial for mediating the necessary interaction between this ]AG hydrolysis by intact neurons in primary culture were both inhibited by treatment with a maximally effective concentration of compound 12 (30 M). **, p Ͻ 0.01; ***, p Ͻ 0.001 (unpaired t test; compared with respective vehicle-treated controls). C, levels of endogenously produced AEA in intact neurons in primary culture after treatment with a maximally effective concentration of compound 12 (30 M) or its vehicle (dimethyl sulfoxide (DMSO)). AEA levels were significantly increased by compound 12 treatment only when the neurons were exposed to stimulating conditions (right). D, levels of endogenously produced 2-AG in intact neurons in primary culture after treatment with a maximally effective concentration of compound 12 (30 M) or its vehicle (dimethyl sulfoxide). 2-AG levels were significantly increased by compound 12 treatment only when the neurons were exposed to stimulating conditions (right). Data are means Ϯ S.E. of three separate experiments. *, p Ͻ 0.05; **, p Ͻ 0.01 (one-way analysis of variance, followed by Dunnett's post-test; compared with basal dimethyl sulfoxide conditions).
soluble protein and the lipophilic environments of its substrates. Although the crystal structure of ABHD6 remains unsolved, this enzyme is predicted to be an integral membrane protein with its active site facing the cytosol, similar to FAAH (25) . Furthermore, based on what is known about the amino acid sequences and putative structures of FAAH and ABHD6, neither of these enzymes is believed to contain a cap domain analogous to the one found close to the MAGL active site. On the other hand, there are also key differences between the active sites of FAAH and ABHD6, such as the amino acid residues that make up their catalytic triads and the surrounding residues that form the binding pocket (26) . Regardless of these considerations, compounds that manage to inhibit FAAH and ABHD6 while sparing MAGL represent useful chemical tools to probe the roles of these enzymes in regulating the eCB signaling system.
Stimulation of neurons in primary culture with glutamate and carbachol does not elevate eCB levels unless the stimulation is combined with inhibitors of eCB hydrolysis, suggesting that, in the absence of any inhibitor, the stimulated production of eCBs is controlled by this hydrolytic enzymatic activity. Inhibition of MAGL supports this point because 2-AG levels are much higher in stimulated neurons when MAGL inhibitors are present (10) . Accordingly, MAGL is known to play an important role in regulating 2-AG levels in neurons (8) , but it has been less clear whether it is possible to significantly increase the stimulated accumulation of 2-AG in these cells by targeting a 2-AG hydrolase other than MAGL (10) . Here, we have reported that compound 12 increases the stimulated accumulation of both AEA and 2-AG in intact neurons, demonstrating that it is indeed possible to augment 2-AG levels in intact neurons in this manner, even when MAGL is fully active. This result lends further credibility to the notion that ABHD6 represents a promising target for the fine-tuned modulation of eCB levels in the nervous system.
In summary, we have described a novel inhibitor of eCB hydrolysis, UCM710 (compound 12), with efficacy in controlling AEA and 2-AG levels in intact neurons by blocking FAAH and ABHD6 activities while preserving MAGL activity. In addition to specific inhibitors for each of these three enzymes, inhibitors of various combinations of the different eCB-hydrolyzing enzymes have been reported as well, but MAGL has consistently been one of the targets of these less selective compounds. Thus, UCM710 represents the first reported compound that inhibits FAAH and ABHD6 without affecting MAGL. We believe that this addition to the pharmacological repertoire provides a valuable tool to assist researchers in the further elucidation of the pathophysiological role of the eCB signaling system and to guide the development of a new generation of therapeutically useful compounds that would selectively target specific aspects of the eCB signaling system.
